Decitabine/paclitaxel co-delivery systems modified with anti-PD-L1 antibodies mediate chemoimmunotherapy for Triple negative breast cancer

被引：0
|
作者：
He, Yang [1 ]
Hu, Qin [2 ]
Wang, Liting [3 ]
Chen, Chuanrong [1 ]
机构：
[1] Department of Oncology, Yijishan Hospital of Wannan Medical College, Wuhu,240001, China
[2] Department of Oncology, Wuhu Hospital Affiliated to East China Normal University, Wuhu,240001, China
[3] Houston Methodist Cancer Center/Weill Cornell Medicine, Houston,TX,77030, United States
来源：
Materials and Design | 2024年 / 237卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Decitabine/paclitaxel co-delivery systems modified with anti-PD-L1 antibodies mediate chemoimmunotherapy for Triple negative breast cancer
    He, Yang
    Hu, Qin
    Wang, Liting
    Chen, Chuanrong
    MATERIALS & DESIGN, 2024, 237
  • [2] Anti-PD-L1 for metastatic triple-negative breast cancer
    Gibson, Josefine
    LANCET ONCOLOGY, 2015, 16 (06): : E264 - E264
  • [3] Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer
    Guo, Beibei
    Qu, Yan
    Sun, Yinping
    Zhao, Songsong
    Yuan, Jiandong
    Zhang, Peizhuo
    Zhong, Zhiyuan
    Meng, Fenghua
    BIOACTIVE MATERIALS, 2023, 25 : 61 - 72
  • [4] Sulindac modulates the response of triple negative breast cancer to anti-PD-L1 immunotherapy
    Yi, Bin
    Ma, Ruixia
    Xi, Yaguang
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer
    Raninga, P.
    Lee, A.
    Sinha, D.
    Shin, Y-Y.
    Mittal, D.
    Kalimutho, M.
    Khanna, K. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
    Cheung, Anthony
    Chenoweth, Alicia M.
    Quist, Jelmar
    Sow, Heng Sheng
    Malaktou, Christina
    Ferro, Riccardo
    Hoffmann, Ricarda M.
    Osborn, Gabriel
    Sachouli, Eirini
    French, Elise
    Marlow, Rebecca
    Lacy, Katie E.
    Papa, Sophie
    Grigoriadis, Anita
    Karagiannis, Sophia N.
    CANCERS, 2022, 14 (14)
  • [7] Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1
    Lafon, Mathilde
    Blaye, Celine
    Kind, Michele
    Bechade, Dominique
    Chassaigne, Florence
    Italiano, Antoine
    Grellety, Thomas
    BREAST JOURNAL, 2019, 25 (05): : 971 - 973
  • [8] A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice
    Liu, Yixuan
    Xie, Ying
    Chen, Yuling
    Duan, Jialun
    Bao, Chunjie
    Wang, Jinling
    Feng, Hexuan
    Wang, Mengjie
    Ren, Yuxin
    Li, Peishan
    Luo, Qian
    Xu, Jiarui
    Jiang, Min
    Men, Yanchen
    Wu, Yang
    Li, Jianwei
    Wang, Guiling
    Lu, Wanliang
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [9] Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer
    Zhang, Nan
    Li, Jing
    Gao, Wenxia
    Zhu, Wangwei
    Yan, Jianqin
    He, Ziyun
    Li, Li
    Wu, Fang
    Pu, Yuji
    He, Bin
    MOLECULAR PHARMACEUTICS, 2022, 19 (09) : 3439 - 3449
  • [10] Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
    Wu, Jinyao
    Chen, Yaokun
    Chen, Lingzhi
    Ji, Zeqi
    Tian, Huiting
    Zheng, Daitian
    Yang, Qiuping
    Liu, Yiyuan
    Cai, Jiehui
    Zheng, Jiehua
    Chen, Yexi
    Li, Zhiyang
    FRONTIERS IN ONCOLOGY, 2023, 12
12345